NLRP3 and cystic fibrosis: Scambler et al. (2019) identified increased levels of IL-18, IL-1β, and caspase-1 activity in the monocytes, epithelia, and serum of CF patients, and these were reversed by pretreatment with NLRP3 inflammasome inhibitors [82].